Philippe Moingeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philippe Moingeon has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Nony
Research Department, Stallergenes Greer, Antony, France
8 shared publications Laurent Mascarell
Research Department, Stallergenes Greer, Antony, France
6 shared publicationsVéronique Baron-Bodo
Research Department, Stallergenes Greer, Antony, France
6 shared publicationsJulien Bouley
Research Department, Stallergenes Greer, Antony, France
4 shared publicationsVincent Lombardi
Research Department, Stallergenes Greer, Antony, France
4 shared publicationsKarine Jain
Research Department, Stallergenes Greer, Antony, France
3 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (3) , 759-770.e13
Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy
- 1 September 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (3) , 759-770.e13
Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy
- 1 April 2017
- Published by Elsevier in Seminars in Immunology
- Vol. 30, 52-60
Differences and similarities between sublingual immunotherapy of allergy and oral tolerance
- 1 April 2017
- Published by Elsevier in Seminars in Immunology
- Vol. 30, 52-60
Differences and similarities between sublingual immunotherapy of allergy and oral tolerance
- 14 February 2017
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 4 (1) , 30-42
Update on Biomarkers to Predict Responders to Allergen Immunotherapy
- 14 February 2017
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 4 (1) , 30-42
Update on Biomarkers to Predict Responders to Allergen Immunotherapy
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 23-31
Enhancing Allergen-Presentation Platforms for Sublingual Immunotherapy
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 23-31
Enhancing Allergen-Presentation Platforms for Sublingual Immunotherapy
- 17 August 2016
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 16 (9) , 1-9
Proteomics for Allergy: from Proteins to the Patients
Proteomics encompasses a variety of approaches unraveling both the structural features, post-translational modifications, and abundance of proteins. As of today, proteomic studies have shed light on the primary structure of about 850 allergens, enabling the design of microarrays for improved molecular diagnosis. Proteomic methods including mass spectrometry allow as well to investigate protein-protein interactions, thus yielding precise information on critical epitopes on the surface of allergens. Mass spectrometry is now being applied to the unambiguous identification, characterization, and comprehensive quantification of allergens in a variety of matrices, as diverse as food samples and allergen immunotherapy drug products. As such, it represents a method of choice for quality testing of allergen immunotherapy products.
- 17 August 2016
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 16 (9) , 1-9
Proteomics for Allergy: from Proteins to the Patients
Proteomics encompasses a variety of approaches unraveling both the structural features, post-translational modifications, and abundance of proteins. As of today, proteomic studies have shed light on the primary structure of about 850 allergens, enabling the design of microarrays for improved molecular diagnosis. Proteomic methods including mass spectrometry allow as well to investigate protein-protein interactions, thus yielding precise information on critical epitopes on the surface of allergens. Mass spectrometry is now being applied to the unambiguous identification, characterization, and comprehensive quantification of allergens in a variety of matrices, as diverse as food samples and allergen immunotherapy drug products. As such, it represents a method of choice for quality testing of allergen immunotherapy products.
- 1 July 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (1) , 305-308
Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects
- 1 July 2016
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 138 (1) , 305-308
Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects
- Open Access
- 1 June 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (25) , 13076-13087
Structural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen
- 1 June 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (25) , 13076-13087
Open AccessStructural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen
- 1 February 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (1) , 161-179
Biomarkers for Allergen Immunotherapy
- 1 February 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (1) , 161-179
Biomarkers for Allergen Immunotherapy
- Open Access
- 11 December 2015
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 168 (2) , 107-109
Will Allergen Fusion Bring New Energy to Immunotherapy?
Although specific immunotherapy is currently only performed with aqueous allergen extracts, second-generation allergy vaccines may rather rely upon well-defined recombinant allergens [1]. The latter represent an attractive alternative to natural allergen extracts, since they can be produced in large quantities with consistent quality. In most circumstances, however, multiple allergens are involved in sensitization, making the recombinant allergen approach very complex as it requires a comprehensive characterization of each individual component of the vaccine. In this context, an interesting strategy is to fuse together several wild-type or mutated allergens, or peptidic fragments, using recombinant DNA technologies (fig. 1). In such fusions, allergens can be further linked to heterologous molecules, used as carriers to enhance stability and immunogenicity (e.g. by facilitating uptake by antigen-presenting cells), thereby creating hybrid or chimeric molecules. Such carrier molecules include, for example, viral proteins such as the rhinovirus or Qβ phage capsid proteins, the pre-S protein from the hepatitis B virus, a modular antigen-translocating moiety, the Fc fragment of an immunoglobulin and the bacterial surface S-layer protein (fig. 1).
- 11 December 2015
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 168 (2) , 107-109
Open AccessWill Allergen Fusion Bring New Energy to Immunotherapy?
Although specific immunotherapy is currently only performed with aqueous allergen extracts, second-generation allergy vaccines may rather rely upon well-defined recombinant allergens [1]. The latter represent an attractive alternative to natural allergen extracts, since they can be produced in large quantities with consistent quality. In most circumstances, however, multiple allergens are involved in sensitization, making the recombinant allergen approach very complex as it requires a comprehensive characterization of each individual component of the vaccine. In this context, an interesting strategy is to fuse together several wild-type or mutated allergens, or peptidic fragments, using recombinant DNA technologies (fig. 1). In such fusions, allergens can be further linked to heterologous molecules, used as carriers to enhance stability and immunogenicity (e.g. by facilitating uptake by antigen-presenting cells), thereby creating hybrid or chimeric molecules. Such carrier molecules include, for example, viral proteins such as the rhinovirus or Qβ phage capsid proteins, the pre-S protein from the hepatitis B virus, a modular antigen-translocating moiety, the Fc fragment of an immunoglobulin and the bacterial surface S-layer protein (fig. 1).